Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists

Abstract

The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R 1 is W is and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

1 . A compound of the formula 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof 
         wherein:
 R 1  is 
 
       
       
         
           
           
               
               
           
         
         
           W is 
         
       
       
         
           
           
               
               
           
         
         
           each R a  is independently H or C 1 -C 4  alkyl; 
           R b  is H; C 1 -C 4  alkyl; cycloalkyl; —N(R 3 )(R 4 ); or phenyl, which is optionally substituted once or twice by alkyl, haloalkyl, —OH, or alkoxy; 
           each R 2  is independently halo; —CN; alkyl; or haloalkyl; 
           R 3  is H or alkyl; 
           R 4  is H or alkyl; 
           R 5  is H, alkyl or —CN; and 
           a is 0, 1 or 2. 
         
       
     
     
         2 . The compound of  claim 1  or a pharmaceutically acceptable salt thereof wherein W is 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound of  claim 1  which is:
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)-6-methylbenzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-amino-1,3,4-oxadiazol-2-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)-6-methylbenzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-amino-1,3,4-oxadiazol-2-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-7a-(5-methyl-1,3,4-oxadiazol-2-yl)-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)-6-methylbenzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)-6-methylbenzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(5-phenyl-1,3,4-oxadiazol-2-yl) octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)-6-ethylbenzonitrile; 
 5-((1R,3aR,6S,7R,7aS)-5,5-difluoro-7-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1,6-dimethyl-3-oxooctahydroisobenzofuran-3a-yl)-1,3,4-oxadiazol-2(3H)-one; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-(tert-butyl)-1H-pyrazol-3-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(5-(tert-butyl)-1-methyl-1H-pyrazol-3-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-7a-(1,5-dimethyl-1H-pyrazol-3-yl)-6,6-difluoro-3,5-dimethyl-1-oxooctahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 2-(6-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(1H-pyrazol-3-yl)octahydroisobenzofuran-4-yl)vinyl)pyridin-3-yl)benzonitrile; 
 6′-((E)-2-((3R,3aS,4R,5S,7aR)-6,6-difluoro-3,5-dimethyl-1-oxo-7a-(1H-pyrazol-3-yl)octahydroisobenzofuran-4-yl)vinyl)-[3,3′-bipyridine]-2-carbonitrile; 
 
       or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A pharmaceutical composition comprising an effective amount of a compound as defined in  claim 1  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         5 . The pharmaceutical composition as defined in  claim 4 , which further comprises a therapeutically effective amount of at least one additional cardiovascular agent. 
     
     
         6 . The pharmaceutical composition as defined in  claim 5 , wherein the at least one additional cardiovascular agent is aspirin or clopidogrel, wherein clopidogrel is a free base or pharmaceutically acceptable salt. 
     
     
         7 . A pharmaceutical composition comprising an effective amount of a compound as defined in  claim 3  or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
     
     
         8 . The pharmaceutical composition as defined in  claim 7 , which further comprises a therapeutically effective amount of at least one additional cardiovascular agent. 
     
     
         9 . The pharmaceutical composition as defined in  claim 8 , wherein the at least one additional cardiovascular agent is aspirin or clopidogrel, wherein clopidogrel is a free base or pharmaceutically acceptable salt. 
     
     
         10 . A method for treating acute coronary syndrome or peripheral artery disease by administering a compound as defined in  claim 1   or a pharmaceutically acceptable salt thereof   
       to a mammal in need of such treatment. 
     
     
         11 . A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound as defined in  claim 1  or a pharmaceutically acceptable salt thereof. 
     
     
         12 . A method for treating acute coronary syndrome or peripheral artery disease by administering a compound as defined in  claim 3   
       or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment. 
     
     
         13 . A method of inhibiting platelet aggregation comprising administering to a mammal an effective amount of a compound as defined in  claim 3   
       or a pharmaceutically acceptable salt thereof.